Ignite Creation Date:
2024-05-05 @ 9:53 PM
Last Modification Date:
2024-10-26 @ 10:11 AM
Study NCT ID:
NCT00989586
Status:
COMPLETED
Last Update Posted:
2017-02-06
First Post:
2009-10-02
Brief Title:
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sponsor:
Organization:
Ohio State University Comprehensive Cancer Center
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
35
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: